Clinical review report: Edoxaban (Lixiana)
Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has r...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, June 2017
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has requested that edoxaban be reimbursed according to the Health Canada indication. The objective of this report was to perform a systematic review of the beneficial and harmful effects of edoxaban for the treatment of VTE (DVT and PE), and for the prevention of recurrent DVT and PE. |
---|---|
Physical Description: | 1 PDF file (ix, 88 pages) illustrations |